Which patient with thyroid cancer deserves systemic therapy and when?
F Pacini - Best Practice & Research Clinical Endocrinology & …, 2017 - Elsevier
Distant metastases from differentiated thyroid cancer (DTC) are a rare event, occurring in
less than 10% of patients with persistent or recurrent clinical disease. About 50% of these …
less than 10% of patients with persistent or recurrent clinical disease. About 50% of these …
Which patient with thyroid cancer deserves systemic therapy and when?
F Pacini - Best Practice & research. Clinical Endocrinology & …, 2017 - europepmc.org
Distant metastases from differentiated thyroid cancer (DTC) are a rare event, occurring in
less than 10% of patients with persistent or recurrent clinical disease. About 50% of these …
less than 10% of patients with persistent or recurrent clinical disease. About 50% of these …
Which patient with thyroid cancer deserves systemic therapy and when?
F Pacini - Best practice & research. Clinical endocrinology …, 2017 - pubmed.ncbi.nlm.nih.gov
Distant metastases from differentiated thyroid cancer (DTC) are a rare event, occurring in
less than 10% of patients with persistent or recurrent clinical disease. About 50% of these …
less than 10% of patients with persistent or recurrent clinical disease. About 50% of these …